Identification of PAthways of Kinase Inhibitors TOxicity

Identification of PAthways of Kinase Inhibitors TOxicity Through Patient Databases

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03896139

Acronym

PAKITO

Enrollment

4000

Registered

2019-03-29

Start date

2017-01-01

Completion date

2019-03-01

Last updated

2019-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kinase Inhibitors Toxicity

Brief summary

The investigators are identifying clinical diagnoses and toxicities associated with kinase inhibitors prescription. This identification will be applied will be applied in an electronic-health-record (EHR) cohort including North American and European.

Interventions

DRUGKinase inhibitor

Patients treated with kinase inhibitors for cancer or other conditions

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patient treated with a kinase inhibitor * Patient identified in the VUMC EHR cohort or having a toxicity reported in the VigiBase

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Comparison of the incidence of kinase inhibitor (KIs) induced toxicities in health records and their associations with co-medications to identify new mechanisms of drug induced toxicity	population included in VUMC database and/or WHO's database resource up to march 2019	Identification of a mechanism of a toxicity associated with a KI using comedications and comparing it to reported outcomes

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026